S&P 500 Futures
(0.82%) 5 124.00 points
Dow Jones Futures
(0.15%) 38 345 points
Nasdaq Futures
(1.10%) 17 762 points
Oil
(0.51%) $84.00
Gas
(-2.93%) $1.590
Gold
(0.21%) $2 347.50
Silver
(0.79%) $27.57
Platinum
(1.18%) $931.40
USD/EUR
(0.07%) $0.932
USD/NOK
(0.11%) $10.96
USD/GBP
(0.04%) $0.800
USD/RUB
(-0.18%) $92.00

Realtime updates for Novo Nordisk A/S [NOVC.DE]

Exchange: XETRA Industry: Pharmaceuticals, Biotechnology & Life Sciences
Last Updated14 Nov 2023 @ 10:35

-1.98% 91.40

Live Chart Being Loaded With Signals

Commentary (14 Nov 2023 @ 10:35):

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products...

Stats
Today's Volume 26 806.00
Average Volume 51 037.00
Market Cap 406.69B
EPS €8.63 ( 2023-06-30 )
Last Dividend €3.00 ( 2023-08-18 )
Next Dividend €0 ( N/A )
P/E 22.91
ATR14 €2.62 (2.86%)

Volume Correlation

Long: 0.32 (neutral)
Short: -0.73 (moderate negative)
Signal:(48.651) Neutral

Novo Nordisk A/S Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novo Nordisk A/S Correlation - Currency/Commodity

The country flag 0.69
( moderate )
The country flag 0.60
( weak )
The country flag -0.76
( moderate negative )
The country flag 0.69
( moderate )
The country flag -0.13
( neutral )
The country flag -0.37
( neutral )

Novo Nordisk A/S Financials

Annual 2022
Revenue: €176.95B
Gross Profit: €148.51B (83.92 %)
EPS: €24.51
Q3 2023
Revenue: €58.73B
Gross Profit: €49.02B (83.46 %)
EPS: €5.02
Q2 2023
Revenue: €54.30B
Gross Profit: €46.44B (85.53 %)
EPS: €8.65
Q1 2023
Revenue: €53.37B
Gross Profit: €45.19B (84.67 %)
EPS: €8.81

Financial Reports:

No articles found.

Novo Nordisk A/S Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€4.25
(N/A)
€0
(N/A)
€8.15
(N/A)
€0
(N/A)
€3.00
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Novo Nordisk A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 6.14 - average (71.63%) | Divividend Growth Potential Score: 4.38 - Stable (12.49%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.670 2002-03-13
Last Dividend €3.00 2023-08-18
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 30 --
Total Paid Out €100.58 --
Avg. Dividend % Per Year 0.00% --
Score 2.88 --
Div. Sustainability Score 6.14
Div.Growth Potential Score 4.38
Div. Directional Score 5.26 --
Next Divdend (Est)
(2024-04-29)
€2.78 Estimate 6.71 %
Dividend Stability
0.27 Very Poor
Dividend Score
2.88
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
WUW.DE Ex Dividend Junior 2023-05-24 Annually 0 0.00%
GDX.DE Ex Dividend Knight 2023-10-05 Quarterly 0 0.00%
PFE.DE Ex Dividend Knight 2023-07-27 Quarterly 0 0.00%
BIJ.DE Ex Dividend Knight 2023-06-21 Sporadic 0 0.00%
HRS.DE Ex Dividend Knight 2023-09-01 Quarterly 0 0.00%
SDF.DE Ex Dividend Junior 2023-05-11 Annually 0 0.00%
CPIA.F No Dividend Player 2023-06-29 Annually 0 0.00%
KSB.DE Ex Dividend Knight 2023-05-05 Annually 0 0.00%
2HRA.DE Ex Dividend Junior 2023-05-24 Sporadic 0 0.00%
TRVC.DE Ex Dividend Junior 2023-08-04 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.3511.5002.984.47[0 - 0.5]
returnOnAssetsTTM0.2511.2001.6351.962[0 - 0.3]
returnOnEquityTTM0.8691.5001.4602.19[0.1 - 1]
payoutRatioTTM0.422-1.0005.78-5.78[0 - 1]
currentRatioTTM0.8240.800-0.880-0.704[1 - 3]
quickRatioTTM0.6350.800-0.971-0.777[0.8 - 2.5]
cashRatioTTM0.1751.500-0.141-0.211[0.2 - 2]
debtRatioTTM0.0884-1.5008.53-10.00[0 - 0.6]
interestCoverageTTM-18.831.000-8.08-8.08[3 - 30]
operatingCashFlowPerShareTTM23.782.002.074.15[0 - 30]
freeCashFlowPerShareTTM17.382.001.3082.62[0 - 20]
debtEquityRatioTTM0.285-1.5008.86-10.00[0 - 2.5]
grossProfitMarginTTM0.8411.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM0.3921.0004.164.16[0.1 - 0.6]
cashFlowToDebtRatioTTM4.011.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.7150.8008.576.85[0.5 - 2]
Total Score6.14

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM40.531.0006.010[1 - 100]
returnOnEquityTTM0.8692.504.512.19[0.1 - 1.5]
freeCashFlowPerShareTTM17.382.004.212.62[0 - 30]
dividendYielPercentageTTM0.4401.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM23.782.002.074.15[0 - 30]
payoutRatioTTM0.4221.5005.78-5.78[0 - 1]
pegRatioTTM0.1421.500-2.380[0.5 - 2]
operatingCashFlowSalesRatioTTM0.4961.0000.09170[0.1 - 0.5]
Total Score4.38

Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators